Scotland's HTA Body Says Fast-Track Yes To UCB’s Bimzelx
Janssen's Ponvory To Be Funded For Relapsing-Remitting MS
The Scottish health technology appraisal body also OKd Janssen's Ponvory and new indications for AstraZeneca’s Tagrisso, Roche’s Tecentriq and MSD’s Keytruda. It also said it could not make recommendations on a number of drugs because manufacturers had not made a submission to the SMC.
You may also be interested in...
Health technology assessment body NICE has also issued guidances rejecting three products.
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.